Much Maligned Manufacturing Site Trips Up Scholar Rock’s Spinal Muscular Atrophy Drug

In its rejection letter, the FDA flagged problems at a third-party fill-finish site owned by Novo Nordisk. Issues at this site have previously been investigated by the regulator.